Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

ZUMA-1 demonstrated a high rate of durable response and a manageable safety profile with axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with refractory large B-cell lymphoma. As previously reported, prespecified clinical covariates for sec...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Blood Adv
Glavni autori: Locke, Frederick L., Rossi, John M., Neelapu, Sattva S., Jacobson, Caron A., Miklos, David B., Ghobadi, Armin, Oluwole, Olalekan O., Reagan, Patrick M., Lekakis, Lazaros J., Lin, Yi, Sherman, Marika, Better, Marc, Go, William Y., Wiezorek, Jeffrey S., Xue, Allen, Bot, Adrian
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2020
Teme:
Immunobiology and Immunotherapy
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7556133/
https://ncbi.nlm.nih.gov/pubmed/33035333
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002394
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items